EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head

Jennifer Clark; Jan Cools; D Gary Gilliland

doi:10.1371/journal.pmed.0020075

EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head

PLoS Med. 2005 Mar;2(3):e75. doi: 10.1371/journal.pmed.0020075. Epub 2005 Feb 22.

Authors

Jennifer Clark¹, Jan Cools, D Gary Gilliland

Affiliation

¹ Harvard Medical School, Brigham and Women's Hospital, and the Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Abstract

Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?

Publication types

Comment

MeSH terms

Antineoplastic Agents / pharmacology
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics*
Drug Resistance, Neoplasm
Enzyme Inhibitors / pharmacology
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics*

Substances

Antineoplastic Agents
Enzyme Inhibitors
ErbB Receptors